It’s a lot of money.
A big chunk of it comes from the U.S.
And it’s not enough.
Those are three things you’ll learn from the sixth annual report on how much money has been spent to improve health in developing countries.
The total in 2014 was $227.9 billion. As impressive as that number sounds, it’s a 1.6 percent drop from 2013.
The U.S. contribution: $143.1 billion. Of course, many other countries chipped in, along with public and private organizations.
The report comes from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Dr. Joseph Dieleman, assistant professor and lead author of the study, spoke with Goats and Soda to provide context. The interview has been edited for length and clarity.
Where does the money come from?
We’re tracking resources from all of the major donors, which include the traditional members of the Organization for Economic Corporation and Development (OECD), such as Australia, Canada, Japan, almost all of the western European countries and more. It also includes private philanthropies: the Bill and Melinda Gates Foundation, for example, gave $2.9 billion of development assistance in health in 2014. The fraction that comes from the U.S last year is 36 percent, which is $12 billion. [The Gates Foundation, as our readers may know, is a supporter of NPR as well.]
What did you learn that you didn’t know before?
One thing we could never do with our data in previous years is link where the money is from, the intermediary channels [institutions like the World Health Organization that provide assistance for global health efforts] and how much money goes into which area. In 2014, for example, 30 percent of development assistance in health went toward HIV/AIDs — about $11 billion. Sixty-three percent is coming from the U.S., which has put significant resources in programs like PEPFAR (The United States President’s Emergency Plan for AIDS Relief).
From 1990 to 2014, a total of $458 billion of development assistance has been provided to improve health in developing countries. Is that enough?
Certainly not enough in the sense that there are diseases that have known cost-effective interventions that still lead to pre-mature mortality throughout the world. That strikes me as evidence that more could be done. Our report essentially lays the groundwork for these discussions. If you don’t know how much is being spent, there’s no way to have that conversation about the effectiveness of development assistance in a meaningful way.